论文部分内容阅读
目的观察雷贝拉唑或奥美拉唑联合莫沙必利(新络纳)治疗老年性反流性食管炎的治疗效果。方法选择食管反流炎患者211例,按照用药方案的不同分为治疗组110例与对照组101例,治疗组口服雷贝拉唑和莫沙必利治疗;对照组口服奥美拉唑和莫沙必利治疗,4周为1个疗程。评价内镜下食管破损黏膜修复和临床症状改善情况及药物不良反应。结果治疗组临床症状改善总有效率96.3%明显高于对照组的85.1%,差异有统计学意义(P<0.05)。治疗组内镜检查改善情况明显优于对照组,差异有统计学意义(P<0.05)。治疗组服药后出现腹泻10例(9.0%),减少莫沙必利剂量后腹泻缓解;口干4例,不影响治疗。2组各有4例丙氨酸转氨酶(ALT)轻度增高,停药后恢复正常。结论雷贝拉唑与莫沙必利联合应用治疗胃食管反流病有效率明显高于奥美拉唑联合莫沙必利。
Objective To observe the therapeutic effect of rabeprazole or omeprazole combined with mosapride (Xinluo Na) in the treatment of senile reflux esophagitis. Methods 211 patients with esophageal reflux disease were selected and divided into treatment group (110 cases) and control group (101 cases) according to different dosage regimen. The treatment group was orally treated with rabeprazole and mosapride; the control group received omeprazole and mo Sabali treatment, 4 weeks for a course of treatment. To evaluate endoscopic esophageal mucosa repair and improvement of clinical symptoms and adverse drug reactions. Results The total effective rate of clinical symptom improvement in the treatment group was significantly higher than that in the control group (96.3% vs 85.1%, P <0.05). The improvement of endoscopic examination in the treatment group was significantly better than that in the control group, with significant difference (P <0.05). In the treatment group, diarrhea occurred in 10 patients (9.0%), relieved the dose of mosapride after diarrhea relief; 4 cases of dry mouth, does not affect the treatment. Four patients in each group had a slight increase in alanine aminotransferase (ALT), returned to normal after withdrawal. Conclusion The combined use of rabeprazole and mosapride in the treatment of gastroesophageal reflux disease was significantly higher than omeprazole combined mosapride.